Goldman Sachs Group Analysts Give GlaxoSmithKline (GSK) a GBX 1,900 Price Target

Goldman Sachs Group set a GBX 1,900 ($24.83) target price on GlaxoSmithKline (LON:GSK) in a report released on Wednesday. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Credit Suisse Group set a GBX 1,450 ($18.95) target price on GlaxoSmithKline and gave the stock a neutral rating in a research report on Monday, July 16th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of GlaxoSmithKline in a research report on Tuesday, October 23rd. UBS Group reaffirmed a buy rating and set a GBX 1,700 ($22.21) target price (up previously from GBX 1,600 ($20.91)) on shares of GlaxoSmithKline in a research report on Monday, July 30th. Deutsche Bank reaffirmed a hold rating and set a GBX 1,525 ($19.93) target price on shares of GlaxoSmithKline in a research report on Thursday, September 6th. Finally, Kepler Capital Markets set a GBX 1,440 ($18.82) target price on GlaxoSmithKline and gave the stock a neutral rating in a research report on Monday, July 30th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of GBX 1,521.27 ($19.88).

LON:GSK opened at GBX 1,480 ($19.34) on Wednesday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).

The business also recently announced a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be given a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 15th. This represents a yield of 1.26%.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply